Catalytic Hydrogenation of Morphinan-6-ones for Stereo-selective 6α-Ol Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic routes for morphinan-6α-ols suffer from low selectivity, resulting in significant contamination with the 6β-isomer, which requires tedious purification processes, including recrystallization or chromatography, making them inefficient and costly.
Innovation Solution
A process involving the catalytic hydrogenation of morphinan-6-ones in an alkaline aqueous solvent with platinum or platinum oxide as a catalyst at a pH between 11 and 14, achieving high selectivity for the 6α-epimer with minimal 6β-epimer contamination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If metal hydride reducing agents (e.g., sodium borohydride, lithium tri-sec-butyl borohydride) are used for reduction of morphinan-6-ones, then the reaction proceeds under mild conditions, but the selectivity is low resulting in significant formation of 6β-isomer contaminant
Solution Approach 1:
The patent changes the fundamental reaction parameters by switching from metal hydride reduction to catalytic hydrogenation conditions. This involves changing the reducing agent type, solvent system (aqueous alkaline conditions), temperature range, and pressure conditions to achieve high stereo-selectivity for the 6α-isomer while minimizing 6β-isomer formation
Solution Approach 2:
The patent replaces the chemical mechanism of metal hydride reduction with a catalytic hydrogenation mechanism using platinum or platinum oxide catalysts. This substitution of reaction mechanism fundamentally changes the stereo-selectivity outcome, achieving >99% selectivity for the desired 6α-isomer
2Manufacturing precision
If low temperatures (e.g., -78°C) or protecting groups are used to improve selectivity, then the 6α-isomer selectivity increases, but the process complexity and cost increase due to special equipment and additional steps
Solution Approach 1:
The patent extracts and eliminates the need for complex protective group chemistry and low-temperature equipment by using catalytic hydrogenation under aqueous alkaline conditions. The method achieves high selectivity without requiring protection/deprotection steps or specialized refrigeration equipment, simplifying the overall process
Solution Approach 2:
The patent employs readily available platinum or platinum oxide catalysts under mild aqueous conditions, replacing expensive protecting group reagents and specialized low-temperature equipment. The catalyst can be easily removed by filtration, making the process economically viable and operationally simple
3Ease of manufacture
If traditional reduction methods are used, then the reaction conditions are well-established, but tedious purification processes (recrystallization or chromatography) are required to remove 6β-isomer contaminant
Solution Approach 1:
The catalytic hydrogenation process essentially purifies itself by achieving such high stereo-selectivity (>99% 6α-isomer) that minimal further purification is needed. The product can be obtained directly after simple filtration to remove the catalyst, eliminating or greatly reducing the need for time-consuming recrystallization or chromatography steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a stereo-selective and environmentally friendly route to produce pure 6α-morphinan-6-ols with less than 1% 6β-epimer impurity, simplifying the purification process and increasing yield, making it commercially viable.
Implementation Method 1
hydrogenating a morphinan-6-one compound of formula (I) in an aqueous solvent and a water soluble base wherein the aqueous solvent is selected from the group consisting of water and a mixture of water and a water-miscible co-solvent in the presence of a catalyst wherein said catalyst is platinum or platinum oxide
Implementation Method 2
catalytic hydrogenation of morphinan-6-ones
Data Source
AI summary
The present invention provides a process whereby morphinan-6-ones can be converted stereospecifically to the corresponding morphinan-6a-ols by catalytic hydrogenation under basic conditions.